PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024
Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. Specifically, adult plaque psoriasis, the most common form of Psoriasis, is the focus of this report. Although not life-threatening, Psoriasis causes tremendous morbidity and personal angst for patients.
GlobalData projects the psoriasis market in 8MM to experience modest growth during the forecast period at a CAGR of 7.26%. This growth will be driven primarily by the highly anticipated arrivals of promising systemic therapies- interleukin-23 (IL-23) inhibitors (guselkumab and tildrakizumab), interleukin-17 (IL-17) inhibitors (Cosentyx, Taltz, and brodalumab) as well as phsophodiesterase (PDE4) inhibitor- Otezla (apremilast). Nevertheless, looming patent expiries of high-grossing branded drugs- especially TNF inhibitors, Humira, Enbrel and Remicade, in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with rapid global developments of biosimilars , are expected to spread the growth throughout the different classes of products, away from the branded TNF inhibitors which have traditionally been the main driver of growth in the prior years.
Key Questions Answered
- How good is the management of Psoriasis with marketed therapies? - Which drugs and players are important in the current management landscape? - What are the most promising late-stage pipeline drugs and how will their launch shape the future treatment landscape in the Psoriasis market? - What are the significant unmet needs and remaining opportunities in the Psoriasis market? - What clinical and commercial factors are likely to uptake of Psoriasis therapies in the US, 5EU, Japan and India?
- The psoriasis market is currently very dynamic, with effective biologic therapies awaiting approval, such as interleukin-17 (IL-17) inhibitor- brodalumab, interleukin-23 (IL-23) inhibitors- guselkumab and tildrakizumab. - Novel biologic therapies will challenge the current anti-TNF biologics in an attempt to dislodge their stronghold, if their safety and efficacy profiles are proven once they enter the market. - The impending patent cliff for biologics will allow for the emergence of biosimilars to all the marketed biologic brands. Patent expiries take place during the forecast period for the current market leaders such as Johnson & Johnson’s Remicade (infliximab), AbbVie’s Humira (adalimumab), Amgen’s Enbrel (etanercept) and Johnson & Johnson’s Stelara (ustekinumab). - The drivers for market growth will also include affordable treatments throughout the world, as well as the push for long-term drug efficacy. The main challenge for individual drugs will be to distinguish themselves in a crowded marketplace, comprising a highly diversified field of therapies, with existing drugs struggling to increase their patient share.
- Overview of Psoriasis, including epidemiology, etiology, pathophysiology, symptoms and current treatment options - Topline Psoriasis market revenue from 2014-2024. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included. - Key topics covered include strategic competitor assessment, unmet needs, pipeline assessment, and market outlook for the Psoriasis market. - Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products- including promising IL-17 and IL-23 inhibitors. - Analysis of the current and future market competition in the global Psoriasis market (8MM). Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to - - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global Psoriasis market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Psoriasis market in the future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Our reports have been used by over 10K customers, including:
219 pages •
By Asia Market Information & Development Company
• Oct 2019
China’s demand for Monoclonal Antibody has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer...
Integrin Alpha 4 - Pipeline Review, H2 2019 Summary Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) pipeline Target constitutes close to 16 molecules. The latest report Integrin Alpha 4 - Pipeline Review, H2 2019, outlays comprehensive information on the...
Integrin Beta 7 - Pipeline Review, H2 2019 Summary Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Integrin beta-7 is an integrin protein encoded by the ITGB7 gene. It interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium...
Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H2 2019 Summary Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) pipeline Target constitutes close to 25 molecules. Out of which approximately...
Tumor Necrosis Factor Receptor Superfamily Member 18 - Pipeline Review, H2 2019 Summary Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357...
Colitis - Pipeline Review, H2 2019 Summary The latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Pipeline Review, H2 2019, provides an overview of the Colitis (Gastrointestinal) pipeline landscape. Colitis is swelling (inflammation) of the large intestine (colon). Colitis...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.